Pantoprazole sodium hydrate
CAS No. 164579-32-2
Pantoprazole sodium hydrate( SKF-96022 sodium hydrate )
Catalog No. M12511 CAS No. 164579-32-2
A proton pump inhibitor that inhibits gastric acid secretion; works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 27 | In Stock |
|
| 100MG | 42 | In Stock |
|
| 200MG | 65 | In Stock |
|
| 500MG | 132 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePantoprazole sodium hydrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionA proton pump inhibitor that inhibits gastric acid secretion; works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
-
DescriptionA proton pump inhibitor that inhibits gastric acid secretion; works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid; inhibits autophagy and increases the toxicity of docetaxel in vitro and in vivo.Ulcer Approved.
-
In VitroPantoprazole sodium hydrate (BY1023 sodium hydrate; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells.Pantoprazole sodium hydrate can block exosome release. Pantoprazole sodium hydrate inhibits the activity of V-H+-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium.
-
In VivoPantoprazole sodium hydrate (BY1023 sodium hydrate; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin. Pantoprazole sodium hydrate (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats. Animal Model:Mice bearing MCF-7 or A431 xenografts Dosage:200 mg/kg Administration:IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.)Result:Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination. Significantly increased tumor growth delay with a single dose with Doxorubicin.
-
SynonymsSKF-96022 sodium hydrate
-
PathwayMembrane Transporter/Ion Channel
-
TargetProton Pump
-
RecptorPotassium-transportingATPase|Protonpump
-
Research AreaOther Indications
-
IndicationUlcer
Chemical Information
-
CAS Number164579-32-2
-
Formula Weight433.38
-
Molecular FormulaC16H15F2N3O4S . 3/2H2 O . Na
-
Purity>98% (HPLC)
-
Solubility10 mM in H2O
-
SMILESO.O.O.[Na+].[Na+].COC1=C(OC)C(CS(=O)C2=NC3=C([N-]2)C=CC(OC(F)F)=C3)=NC=C1.COC1=C(OC)C(CS(=O)C2=NC3=C([N-]2)C=CC(OC(F)F)=C3)=NC=C1
-
Chemical Name1H-Benzimidazole, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt, hydrate (2:2:3)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tan Q, et al. Br J Cancer. 2015 Mar 3;112(5):832-40.
2. Feng S, et al. Oncol Rep. 2016 Dec;36(6):3207-3214.
3. Zeng X, et al. Oncotarget. 2016 Apr 19;7(16):22460-73.
molnova catalog
related products
-
Ilaprazole sodium
Ilaprazole is a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity.
-
Lansoprazole sodium
Lansoprazole sodium is a proton pump inhibitor (PPI) and a potent inhibitor of gastric acidity which is widely used in the therapy of gastroesophageal reflux and peptic ulcer disease.
-
Esomeprazole
Esomeprazole is the S-isomer of omeprazole, inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis.
Cart
sales@molnova.com